Overview

CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma

Status:
Not yet recruiting
Trial end date:
2025-04-15
Target enrollment:
Participant gender:
Summary
This is a prospective, single arm, multicenter, dose-escalation clinical study to evaluate the safety and efficacy of CMOEP in patients with untreated Peripheral T-cell Lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Collaborator:
CSPC Ouyi Pharmaceutical Co., Ltd.
Treatments:
Cyclophosphamide
Etoposide
Mitoxantrone
Prednisone
Vincristine